Charles Ornstein

With open enrollment over for private health insurance, states are struggling to process hundreds of thousands of Medicaid applications.

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published today in the Journal of the American Medical Association.

One day very soon, the focus on Obamacare will turn from signing up new enrollees to quantifying the law’s success — or failure.

Twice last week, the Centers for Disease Control and Prevention had pointed to the harm caused by aberrant and inappropriate prescribing by physicians.

In a major departure from industry practice, GlaxoSmithKline, the sixth-largest global drug maker, announced Tuesday that it will no longer hire doctors to promote its drugs.

With open enrollment over for private health insurance, states are struggling to process hundreds of thousands of Medicaid applications.

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published today in the Journal of the American Medical Association.

One day very soon, the focus on Obamacare will turn from signing up new enrollees to quantifying the law’s success — or failure.

Twice last week, the Centers for Disease Control and Prevention had pointed to the harm caused by aberrant and inappropriate prescribing by physicians.

In a major departure from industry practice, GlaxoSmithKline, the sixth-largest global drug maker, announced Tuesday that it will no longer hire doctors to promote its drugs.